Work

Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study.

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.1044

Authors: Sami Diab, Hope S. Rugo, Lida A. Mina, Shannon Puhalla, Reshma L. Mahtani, Norah Lynn Henry, Neelima Denduluri, Denise A. Yardley, Yao Wang, Lillian Shahied Arruda, Iulia Cristina Tudor, Eric Roland Gauthier, Akos Gabor Czibere, Jennifer Keating Litton, Sara A. Hurvitz

Institutions: University of Colorado Cancer Center, UCSF Helen Diller Family Comprehensive Cancer Center, Banner Health, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Sylvester Comprehensive Cancer Center, Huntsman Cancer Institute, Virginia Cancer Specialists, Sarah Cannon, Pfizer (United States), The University of Texas MD Anderson Cancer Center, University of California, Los Angeles

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2947996306

Cites:

Cited by: 1

Related to: 10